6 research outputs found
The HRCT image analysis for quantitative description of peripheral airways remodelling
Airways remodelling is currently described as a process occurring before asthma becomes clinically manifest, which is confirmed by biopsy studies. The aim of this study was to test and validate image analysis methods to describe the changes such as peripheral airways remodelling in HRCT readings. Different methods of airways extraction from HRCT images were investigated including: manual identification of an airway region major axes on original and scaled images (using different interpolation techniques like pixel resize, bilinear interpolation and cubic convolution), manual extraction of the density profile through the major axes of an airway region, semi-automatic method using active contours and the Hough transform. Methods were tested with original images and artificially modified images by blurring and noise addition (Gaussian, Laplacian and salt-and-pepper). Results suggest that popular image magnification using cubic convolution is not suitable for accurate estimation of shape properties of small regions. Smart pixel resizing enables to delineate a region of inner and outer borders with subpixel accuracy reducing the total error of the wall thickness estimation. Additionally smoothing must be reduced to the minimum in the case of an active contour application
Asthma control in patients with asthma and allergic rhinitis receiving add-on montelukast therapy for 12 months: a retrospective observational study
Adjusted subpixel method enables optimisation of bronchial measurements in high-resolution CT
Optical coherence tomography angiography vessel density in children with type 1 diabetes
Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone
BACKGROUND:
The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate.
METHODS:
In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in the year before randomization but not during the previous month. Patients were excluded from the trial if they had a history of life-threatening or unstable asthma. The primary safety end point was the first serious asthma-related event (death, endotracheal intubation, or hospitalization). Noninferiority of fluticasone-salmeterol to fluticasone alone was defined as an upper boundary of the 95% confidence interval for the risk of the primary safety end point of less than 2.0. The efficacy end point was the first severe asthma exacerbation.
RESULTS:
Of 11,679 patients who were enrolled, 67 had 74 serious asthma-related events, with 36 events in 34 patients in the fluticasone-salmeterol group and 38 events in 33 patients in the fluticasone-only group. The hazard ratio for a serious asthma-related event in the fluticasone-salmeterol group was 1.03 (95% confidence interval [CI], 0.64 to 1.66), and noninferiority was achieved (P=0.003). There were no asthma-related deaths; 2 patients in the fluticasone-only group underwent asthma-related intubation. The risk of a severe asthma exacerbation was 21% lower in the fluticasone-salmeterol group than in the fluticasone-only group (hazard ratio, 0.79; 95% CI, 0.70 to 0.89), with at least one severe asthma exacerbation occurring in 480 of 5834 patients (8%) in the fluticasone-salmeterol group, as compared with 597 of 5845 patients (10%) in the fluticasone-only group (P<0.001).
CONCLUSIONS:
Patients who received salmeterol in a fixed-dose combination with fluticasone did not have a significantly higher risk of serious asthma-related events than did those who received fluticasone alone. Patients receiving fluticasone-salmeterol had fewer severe asthma exacerbations than did those in the fluticasone-only group